NCI-H3122-CR1 (Q54872053)

From Wikidata

Jump to navigation Jump to search

cell line

NCI-H3122 CR1
H3122 CR1

Language	Label	Description	Also known as
English	NCI-H3122-CR1	cell line	NCI-H3122 CR1 H3122 CR1

Statements

1 reference

Cellosaurus release 49

14 July 2024

cancer cell line

1 reference

Cellosaurus release 49

14 July 2024

parent cell line

1 reference

Cellosaurus release 49

14 July 2024

described by source

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

1 reference

Cellosaurus release 49

14 July 2024

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

1 reference

Cellosaurus release 49

14 July 2024

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

1 reference

Cellosaurus release 49

14 July 2024

established from medical condition

adenocarcinoma of the lung

1 reference

Cellosaurus release 49

14 July 2024

derived from organism type

1 reference

Cellosaurus release 49

14 July 2024

Identifiers

1 reference

Cellosaurus release 49

14 July 2024

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54872053&oldid=2258231615"